You just read:

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland

News provided by

Daiichi Sankyo Company, Limited

15 Apr, 2015, 07:00 BST